| Zeit | Aktuelle Nachrichten
| | Leser | Medien |
|---|
| 21.05.
| Discovery Laboratories: A Hidden Gem In Biotech | | 4 | Seeking Alpha |
| 11.05.
| Possible Bullish Inside Day Candle Pattern Detected for Discovery Laboratories | | 7 | SmarTrend |
| 04.05.
| Discovery Laboratories: Surfaxin Shows Compelling Advantages With Animal Surfactants | | 10 | Seeking Alpha |
| 03.05.
| Discovery Labs Reports First Quarter 2012 Financial Results | | 18 | PR Newswire |
| WARRINGTON, Pa., May 3, 2012 /PRNewswire/ --Discovery Laboratories, Inc. (Nasdaq: DSCO), a specialty biotechnology company dedicated to advancing a new standard in respiratory critical care, today...
Mehr lesen zu:
Discovery Labs Reports First Quarter 2012 Financial Results | |
| 27.04.
| DISCOVERY LABORATORIES INC /DE/ - 10-K/A, Annual Report | | 1 | SEC Filings |
| 23.04.
| Large Pharmaceuticals Look to Smaller Biotech Companies to Combat Losses From Expiring Patents / The Paragon Report Provides Stock Research on Discovery Laboratories, Inc. and MannKind Corp. | | 45 | MarketWire |
| NEW YORK, NY -- (Marketwire) -- 04/23/12 -- Mergers and Acquisitions have been a hot topic in in the Biotechnology Industry recently. Pharmaceutical giants face an unprecedented number of patent expirations...
Mehr lesen zu:
Large Pharmaceuticals Look to Smaller Biotech Companies to Combat Losses From Expiring Patents / The Paragon Report Provides Stock Research on Discovery Laboratories, Inc. and MannKind Corp. | |
| 21.03.
| Discovery Labs (DSCO) Closes 16.07M Offering at $2.80/Share | | 9 | StreetInsider.com |
| 07.03.
| Media Alert: Discovery Labs to Hold Conference Call to Discuss FDA Approval of SURFAXIN® (lucinactant) | | 46 | PR Newswire |
| WARRINGTON, Pa., March 7, 2012 /PRNewswire/ --Discovery Laboratories, Inc. (NASDAQ: DSCO), a specialty biotechnology company dedicated to advancing a new standard in respiratory critical care, will...
Mehr lesen zu:
Media Alert: Discovery Labs to Hold Conference Call to Discuss FDA Approval of SURFAXIN® (lucinactant) | |
| 06.03.
| UPDATE 1-FDA approves Discovery Lab's lung drug | | 2 | Reuters.com |
| 06.03.
| Discovery Labs (DSCO) Gets FDA Approval for Surfaxin to Prevent RDS in Premature Infants at High Risk | | 4 | StreetInsider.com |
| 06.03.
| Discovery Labs Announces FDA Approval of SURFAXIN® (lucinactant) for Prevention of Respiratory Distress Syndrome | | 58 | PR Newswire |
| WARRINGTON, Pa., March 6, 2012 /PRNewswire/ -- Discovery Laboratories, Inc. (NASDAQ: DSCO), a specialty biotechnology company dedicated to advancing a new standard in respiratory critical care, today...
Mehr lesen zu:
Discovery Labs Announces FDA Approval of SURFAXIN® (lucinactant) for Prevention of Respiratory Distress Syndrome | |
| 08.02.
| Discovery Labs (DSCO) Enters into AFECTAIR Manufacturing Agreement | | - | StreetInsider.com |
| 08.02.
| Discovery Laboratories (DSCO) Enters Manufacturing Agreement for AFECTAIR | | 3 | StreetInsider.com |
| 08.02.
| Discovery Labs Signs Manufacturing Agreement for AFECTAIR® | | 38 | PR Newswire |
| WARRINGTON, Pa., Feb. 8, 2012 /PRNewswire/ --Discovery Laboratories, Inc. (NASDAQ: DSCO), a specialty biotechnology company dedicated to advancing a new standard in respiratory critical care, today...
Mehr lesen zu:
Discovery Labs Signs Manufacturing Agreement for AFECTAIR® | |
| 02.02.
| Discovery Labs Cleared to Market AFECTAIR in U.S. | | 33 | PR Newswire |
| WARRINGTON, Pa., Feb.2, 2012 /PRNewswire/ --Discovery Laboratories, Inc. (NASDAQ: DSCO), a specialty biotechnology company dedicated to advancing a new standard in respiratory critical care, today...
Mehr lesen zu:
Discovery Labs Cleared to Market AFECTAIR in U.S. | |
